Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.538
Buy
RSI(14)
62.529
Neutral
STOCH(KDJ)(9,3,3)
88.403
Overbought
ATR(14)
0.729
High Vlolatility
CCI(14)
115.223
Buy
Williams %R
10.526
Overbought
TRIX(12,20)
0.361
Sell
StochRSI(14)
76.116
Sell
Search
Omeros Corp
OMERAdd to Watchlist
11.850USD
-0.080-0.67%
Close 07-31 16:00（ET）Quotes delayed by 15 min
830.37MMarket Cap
9.09P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.67%
5 Days
+21.04%
1 Month
+25.93%
6 Months
+1.37%
Year to Date
-31.00%
1 Year
+206.20%
Key Figures
11.920Open
11.990High
1.31MVolume
9.09P/E TTM
LossP/E Dynamic
--Dividend TTM
1.87%Turnover Ratio
11.930Prev. Close
11.370Low
10.85MTurnover
LossP/E Static
-3.77P/B
0.00%Div Yield TTM
32.23%ROA
17.65052wk High
0.70Volume Ratio
-156.81MNet Profit
70.07MShares
1.3031EPS TTM
2.55Beta
-576.33%ROE
2.95052wk Low
5.20%Amplitude
94.07%Gross Margin
830.37MMarket Cap
6.27Reward/Risk
4.56%Risk Rate
TradingKey Stock Score of Omeros Corp
Currency: USD Updated: 2026-07-31Key Insights
Omeros Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 95 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 44.00.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Omeros Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Omeros Corp Highlights
StrengthsRisks
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Overvalued
The company’s latest PE is 9.09, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 38.03M shares, increasing 4.51% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 79.13K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.05.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
44.000
Target Price
+277.04%
Upside Space
Omeros Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
4
analysts
Buy
Current Rating
44.000
Target Price
+277.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Omeros Corp
OMER
4
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
11.612
Buy
MA10
10.713
Buy
MA20
10.419
Buy
MA50
10.336
Buy
MA100
11.384
Buy
MA200
10.977
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Omeros Corp Info
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Ticker SymbolOMER
CompanyOmeros Corp
CEODemopulos (Gregory A)
Websitehttps://www.omeros.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Omeros Corp (OMER)?
The current price of Omeros Corp (OMER) is 11.85.
What is the symbol of Omeros Corp?
The ticker symbol of Omeros Corp is OMER.
What is the 52-week high of Omeros Corp?
The 52-week high of Omeros Corp is 17.65.
What is the 52-week low of Omeros Corp?
The 52-week low of Omeros Corp is 2.95.
What is the market capitalization of Omeros Corp?
The market capitalization of Omeros Corp is 830.37M.
Is Omeros Corp (OMER) currently rated as Buy, Hold, or Sell?
According to analysts, Omeros Corp (OMER) has an overall rating of Buy, with a price target of 44.00.
What is the Earnings Per Share (EPS TTM) of Omeros Corp (OMER)?
The Earnings Per Share (EPS TTM) of Omeros Corp (OMER) is -0.05.